drugset
drugset / Trial / NCT05616923

Topical Mitogenic-Activated Protein Kinase (MAPK) Inhibition in Rosacea

NCT05616923 ↗

Phase 1 Completed 12 enrolled Albany Research Institute, Inc.
RandomizedSingle-groupQuadruple-blindTreatment

Summary

This is a prospective, vehicle controlled, double blinded study to evaluate the safety and potential efficacy of a topical formulation of a MEK inhibitor in patients with erythematotelangiectatic rosacea

Timeline

Start
2021-11-01
Primary completion
2022-12-31
Completion
2022-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Trametinib Small molecule 0.1 unknown Topical

Indications

rosacea